229 related articles for article (PubMed ID: 33579816)
41. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
42. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
43. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
44. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
45. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
[TBL] [Abstract][Full Text] [Related]
46. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
47. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
48. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
49. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
[TBL] [Abstract][Full Text] [Related]
50. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
51. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
52. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
Morkel M; Riemer P; Bläker H; Sers C
Oncotarget; 2015 Aug; 6(25):20785-800. PubMed ID: 26299805
[TBL] [Abstract][Full Text] [Related]
53. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
54. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
55. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
56. BRAF testing in advanced colorectal cancer: is it ready for prime time?
Phillips B; Kalady M; Kim R
Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
[TBL] [Abstract][Full Text] [Related]
57. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
58. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
59. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
60. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
